Get started
Keyword

abemaciclib

Description: An anticancer drug that inhibits cyclin-dependent kinases 4 and 6 and is used in the treatment of certain breast cancers.
Wikidata ID: wiki/Q23901483
OpenAlex ID: keywords/abemaciclib
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
2017 · Matthew P. Goetz, Masakazu Toi, et al. · Journal of Clinical Oncology · 1,735
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 · George W. Sledge, Masakazu Toi, et al. · Journal of Clinical Oncology · 1,677
Treating cancer with selective CDK4/6 inhibitors
2016 · Ben O'Leary, Richard S. Finn, et al. · Nature Reviews Clinical Oncology · 1,128
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
2020 · Stephen R. D. Johnston, Nadia Harbeck, et al. · Journal of Clinical Oncology · 1,042
PDF
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
2019 · George W. Sledge, Masakazu Toi, et al. · JAMA Oncology · 987
PDF
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
2016 · Amita Patnaik, Lee S. Rosen, et al. · Cancer Discovery · 741
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening
2018 · Helen H.N. Yan, Hoi Cheong Siu, et al. · Cell stem cell · 719
PDF
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
2019 · Stephen Johnston, Miguel Martin, et al. · npj Breast Cancer · 682
PDF
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
2017 · Maura N. Dickler, Sara M. Tolaney, et al. · Clinical Cancer Research · 676
PDF
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
2017 · Kurt Engeland · Cell Death and Differentiation · 656
PDF
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
2020 · Lei Ding, Jiaqi Cao, et al. · International Journal of Molecular Sciences · 618
PDF
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
2022 · Stephen R D Johnston, Masakazu Toi, et al. · The Lancet Oncology · 600
PDF
Targeting CDK4/6 in patients with cancer
2016 · Erika Hamilton, Jeffrey R. Infante · Cancer Treatment Reviews · 481
PDF
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
2020 · Laura M Spring, Seth A Wander, et al. · The Lancet · 471
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
2018 · David A. Schaer, Richard P. Beckmann, et al. · Cell Reports · 467
PDF
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
2020 · C. Louwrens Braal, Elisabeth M. Jongbloed, et al. · Drugs · 439
PDF
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
2016 · Ping Chen, Nathan V. Lee, et al. · Molecular Cancer Therapeutics · 429
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
2015 · Todd VanArsdale, Chris Boshoff, et al. · Clinical Cancer Research · 394
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
2018 · Robert Roskoski · Pharmacological Research · 393
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
2021 · N. Harbeck, P. Rastogi, et al. · Annals of Oncology · 381
PDF
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
2018 · Kamal Pandey, Hee‐Jung An, et al. · International Journal of Cancer · 362
PDF
Cell-Cycle Therapeutics Come of Age
2017 · Matthew Ingham, Gary K. Schwartz · Journal of Clinical Oncology · 353
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
2015 · Thomas J. Raub, Graham N. Wishart, et al. · Drug Metabolism and Disposition · 282
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
2020 · Sara M Tolaney, Andrew M Wardley, et al. · The Lancet Oncology · 258
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
2019 · Marc Hafner, Caitlin E. Mills, et al. · Cell chemical biology · 250
PDF
Works count: 4,076
Citation count: 44,600
Year
Topic
Type